Sciagrà, Roberto http://orcid.org/0000-0003-0694-2552
,
Lubberink, Mark
Hyafil, Fabien
Saraste, Antti
Slart, Riemer H. J. A.
Agostini, Denis
Nappi, Carmela
Georgoulias, Panagiotis
Bucerius, Jan
Rischpler, Christoph
Verberne, Hein J.
Funding for this research was provided by:
Università degli Studi di Firenze
Article History
Received: 18 August 2020
Accepted: 17 September 2020
First Online: 2 November 2020
Compliance with ethical standards
:
: Mark Lubberink is co-founder and part-time employee of MedTrace Pharma A/S. Fabien Hyafil is consultant for Naogen. Antti Saraste is supported by grants from the Finnish Cardiovascular Foundation and Academy of Finland, has received consulting fees from Astra Zeneca and Amgen, and has received speaker fees from Astra Zeneca, Abbott, Amgen, Bayer and Novartis. All the other authors declare that they have no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: This guideline summarises the views of the EANM Cardiovascular Committee. It reflects recommendations for which the EANM cannot be held responsible. The recommendations should be taken into context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.